TRPM4 and status epilepticus: Hippocampal cell loss is a common characteristic of SE both in rodents and human patients.43,44 Interestingly, it has been shown earlier that glibenclamide—a non-specific TRPM4 antagonist—can improve cell loss in status epilepticus.45 Among other cell types, hilar MCs are the most vulnerable to epileptic insults.46 Here, we demonstrated that meclofenamate treatment reduced MC loss after KA injection.